**Core Concept**
The question appears to be testing the management of a hypopigmented patch, likely vitiligo, given the description of the condition in an 18-year-old female. The core concept involves understanding the treatment options available for this condition, which typically include topical corticosteroids, phototherapy, and immunomodulators.

**Why the Correct Answer is Right**
Vitiligo is an autoimmune condition characterized by the loss of pigment-producing melanocytes. Treatment options aim to promote repigmentation or camouflage the affected areas. Topical corticosteroids, such as triamcinolone, are commonly used to suppress inflammation and promote repigmentation. Phototherapy, including ultraviolet B (UVB) light, is also effective in repigmenting affected areas. Immunomodulators, like tacrolimus, can help reduce inflammation and promote repigmentation. However, one treatment option is not typically used for vitiligo.

**Why Each Wrong Option is Incorrect**
**Option A:** Topical corticosteroids are commonly used for vitiligo treatment, so this option is incorrect.
**Option B:** Phototherapy, including UVB light, is a standard treatment for vitiligo, making this option incorrect.
**Option C:** Immunomodulators, such as tacrolimus, are also used to treat vitiligo, so this option is incorrect.

**Clinical Pearl / High-Yield Fact**
One key point to remember is that surgical treatment, such as skin grafting or melanocyte transfer, is not a standard treatment for vitiligo, as it is often associated with a high risk of recurrence and scarring.

**Correct Answer: D.**